Navigation Links
Compendia Bioscience Announces the Receipt of a $2.4M SBIR Award and Related Management Changes
Date:10/11/2007

ANN ARBOR, Mich., Oct. 11 /PRNewswire/ -- Compendia Bioscience, Inc. today announced the receipt of a $2.4 million SBIR Fast Track Award from the National Cancer Institute to support the project entitled "Development of Oncomine Professional as a Platform for Biopharmaceutical Research and Development".

(Logo: http://www.newscom.com/cgi-bin/prnh/20070213/NYTU093LOGO )

Compendia co-founder Dan Rhodes Ph.D., who will serve as the principal investigator for this project, will assume a full time position at Compendia Bioscience as Chief Executive Officer. Current CEO John Freshley will remain with the company as Chief Business Officer overseeing sales, marketing and corporate development.

"We are thrilled with this award from the NCI and are looking forward to executing the project, which we expect will lead to increased applicability of Oncomine Professional to drug discovery and development," said Dr. Rhodes. "And on a personal level, I am excited to have the opportunity to increase my level of commitment to Compendia."

"Compendia was founded in 2006 to extend Oncomine the commercial sector. Over the past year we have seen ever increasing acceptance of Oncomine in the biopharmaceutical arena, and with that growing sales, marketing, and business development demands," commented John Freshley. "I am looking forward to concentrating on the continued commercial adaptation of this important product."

Oncomine, a dynamic system that combines a rapidly growing compendium of 20,000+ cancer transcriptome profiles with a sophisticated analysis engine and a powerful web application for data mining and visualization, facilitates rapid and reliable biomarker and therapeutic target discovery, validation, and prioritization.

The NIH Fast-Track application process expedites award decisions and funding of SBIR Phase II applications for scientifically meritorious projects that have a high potential for commercialization. The Fast-Track process allows Phase I and II grant applications to be submitted and reviewed together.

About Compendia Bioscience, Inc. Compendia Bioscience is dedicated to harnessing the global collection of high throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes."


'/>"/>
SOURCE Compendia Bioscience, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Bioscience clusters: Too many or room for more?
5. Quintessence Biosciences names new president
6. Caden Biosciences may signal critical mass
7. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
8. WARF signs licensing pact with BD Biosciences
9. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
10. Bioscience beats beer
11. State awards QRG Biosciences development grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
Breaking Biology News(10 mins):